| Literature DB >> 16985884 |
Abstract
Reimbursement issues surrounding the treatment of prostate cancer with hormonal therapies have changed dramatically in the past 2 years. The ultimate goal for urologists when making treatment decisions regarding LHRH agonist use is to continue to provide hassle-free, complete care for patients, including whatever medications they need. This is still fully possible under the new rules without sacrificing the opportunity to profit from office-based administration of injectable medications.Entities:
Year: 2005 PMID： 16985884 PMCID： PMC1477618
Source DB: PubMed Journal: Rev Urol ISSN： 1523-6161